Hengrui and Kailera cleared their path for a new victory

Introduction

Kailera Therapeutics is a leading clinically inspired biopharmaceutical company with its footprint in the healthcare sector since October 2024. The company is dedicated towards increasing the number of future effective therapies in its portfolio for suitable metabolic conditions and obesity. The company’s comprehensive pipeline and collaborations are its biggest business strength.

Hengrui Pharma, also known as Jiangsu Hengrui Pharmaceuticals Co., Ltd, stands tall on its innovation initiatives for immunology, metabolic diseases and oncology fields. The company’s operations and R&D centers are the heart of the business and a huge support to Europe, Japan, China and the US clinical settings and healthcare units.

Announcement

Hengrui and Kailera, after clearing mid-stage China’s Oral GLP-1/GIP Pill study, opened a new path for the Phase 3 study. Alongside, the companies have moved towards their individual goal in their respective operations, as Hengrui will give a pump to its valuable asset in this Phase 3 study in China. Whereas, Kailera will introduce a Phase 2 study of ribupatide.

Overall, the obesity space will witness new solutions to its promising portfolio soon. This recent mid-stage winning moment was for the company's partner-based study for ribupatide, which is ready to sell it as a weight loss pill with the proven achievement of 12% in the adult population with obesity.

Recent Update

Recently, after clearing the mid scenario, in China, the companies are initiating a Phase 2 study with 166 obese patients who will be dosed with one of three effective ribupatide doses (10 mg, 25 mg or 50 mg or placebo). The study involved 26 weeks follow up, after which the two high-volume drug doses went down at 12.1% in weight reduction for the ground stage, and one dose on placebo managed to reduce 2.3% of weight. The plateauing impact is not registered yet.

Continuing this study, the 59.1% patient cohort dosed with 25 mg experienced 10% weight loss and 38.6% loss, 15% of weight loss at 26 weeks. The percentages recorded under the 25 mg cohort proved low in comparison to the 50 mg cohort. Though both companies performed the safety procedure and recorded it.

Companies have decided to continue with the same dosages and treatments. As of now, Novo Nordisk is the hero of the oral obesity field, but Kailera and Hengrui are in line to compete with Novo in the near future for sure.